CORRECTION
Correction: Iodide Protects Heart Tissue from Reperfusion Injury Akiko Iwata, Michael L. Morrison, Mark B. Roth
The authors wish to amend the Competing Interests statement for this article, which should have included additional information in relation to potential competing interests relevant to this work. The authors apologize for this omission and revise the Competing Interests statement to read as below. The authors have read PLOS ONE's competing interests policy, and they have the following to declare: Dr. Roth is President, Founder, and a member of the Board of Directors for Faraday Pharmaceuticals, a company dedicated to promoting iodide therapy for ischemic injury. Dr. Roth and his co-authors, Drs. Iwata and Morrison, own stock in the company. Additionally, the authors are named on pending patent applications for iodide therapy (Use of Halogen Compounds For the Treatment and Prevention of Heart Attack and Ischemic Injury). This does not affect or alter our adherence to all of PLOS ONE's policies on sharing data and materials.
Reference 1.
Iwata A, Morrison ML, Roth MB (2014) Iodide Protects Heart Tissue from Reperfusion Injury. PLoS ONE 9(11): e112458. doi: 10.1371/journal.pone.0112458 PMID: 25379708
OPEN ACCESS Citation: Iwata A, Morrison ML, Roth MB (2015) Correction: Iodide Protects Heart Tissue from Reperfusion Injury. PLoS ONE 10(9): e0138396. doi:10.1371/journal.pone.0138396 Published: September 14, 2015 Copyright: © 2015 Iwata et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PLOS ONE | DOI:10.1371/journal.pone.0138396 September 14, 2015
1/1
Correction: Iodide Protects Heart Tissue from Reperfusion Injury Akiko Iwata, Michael L. Morrison, Mark B. Roth
The authors wish to amend the Competing Interests statement for this article, which should have included additional information in relation to potential competing interests relevant to this work. The authors apologize for this omission and revise the Competing Interests statement to read as below. The authors have read PLOS ONE's competing interests policy, and they have the following to declare: Dr. Roth is President, Founder, and a member of the Board of Directors for Faraday Pharmaceuticals, a company dedicated to promoting iodide therapy for ischemic injury. Dr. Roth and his co-authors, Drs. Iwata and Morrison, own stock in the company. Additionally, the authors are named on pending patent applications for iodide therapy (Use of Halogen Compounds For the Treatment and Prevention of Heart Attack and Ischemic Injury). This does not affect or alter our adherence to all of PLOS ONE's policies on sharing data and materials.
Reference 1.
Iwata A, Morrison ML, Roth MB (2014) Iodide Protects Heart Tissue from Reperfusion Injury. PLoS ONE 9(11): e112458. doi: 10.1371/journal.pone.0112458 PMID: 25379708
OPEN ACCESS Citation: Iwata A, Morrison ML, Roth MB (2015) Correction: Iodide Protects Heart Tissue from Reperfusion Injury. PLoS ONE 10(9): e0138396. doi:10.1371/journal.pone.0138396 Published: September 14, 2015 Copyright: © 2015 Iwata et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PLOS ONE | DOI:10.1371/journal.pone.0138396 September 14, 2015
1/1
